Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00965731 · ClinicalTrials.gov registry record · Phase 1
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 16
- Study locations
NCT00965731 is a Phase 1 study of Non-Small Cell Lung Cancer that has completed, run by Pfizer. The registered enrollment target is 27 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (96% lower). The trial reports 16 study locations across 7 states.
The verdict
NCT00965731, a Phase 1 study of Non-Small Cell Lung Cancer, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a Phase 1/2 study comparing the safety and anti-tumor activity of erlotinib alone versus erlotinib in combination with PF-02341066 in patients with advanced non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG Erlotinib
- DRUG PF-02341066
Study Locations (16)
Missouri
- Siteman Cancer Center - City of Saint Peters
- Siteman Cancer Center -West County - Creve Coeur
- Barnes-Jewish Hospital - St Louis
- Washington University, School of Medicine - St Louis
California
- University of California, Irvine Medical Center Pharmacy - Orange
- University of California, Irving - Medical Center - Orange
- University of California Irvin - Orange
Ohio
- OSU East - Columbus
- The Ohio State University James Cancer Hospital - Columbus
- James Care in Kenny - Columbus
Alabama
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham - Birmingham
Washington
- Seattle Cancer Care Alliance - Seattle
- University of Washington Medical Center - Seattle
Florida
- Holy Cross Hospital - Fort Lauderdale
Texas
- Cancer Therapy & Research Center @ UTHSCSA - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00965731
The ClinicalTrials.gov registry entry for NCT00965731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Erlotinib is the first listed.
NCT00965731 reports 16 study locations spanning 7 distinct geographic areas - top geographies include Missouri, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT00965731 about?
NCT00965731 is a clinical study titled "Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer". This is a Phase 1/2 study comparing the safety and anti-tumor activity of erlotinib alone versus erlotinib in combination with PF-02341066 in patients with advanced non-small cell lung cancer.
What is the current status of trial NCT00965731?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2010-01. Estimated completion is 2014-01.
What conditions does trial NCT00965731 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT00965731?
The interventions under investigation include: Erlotinib (DRUG), PF-02341066 (DRUG).
Who is sponsoring clinical trial NCT00965731?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00965731 being conducted?
This trial has 16 study locations across Alabama, California, Florida, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.